Press Releases Events & Presentations Events & Presentations Featured Events Apr 17 - Apr 21, 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Supporting Materials Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB ABI-5366-101: A Phase 1b Study of a Novel, Oral, Long-Acting, Investigational HSV Helicase-Primase Inhibitor in Recurrent Genital Herpes 394.7 KB The Efficacy, Safety, and Pharmacokinetics of ABI-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results From a Phase 1b Study 589.2 KB Presentations Assembly Biosciences Corporate Presentation Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Events & Presentations Featured Events Apr 17 - Apr 21, 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Supporting Materials Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB ABI-5366-101: A Phase 1b Study of a Novel, Oral, Long-Acting, Investigational HSV Helicase-Primase Inhibitor in Recurrent Genital Herpes 394.7 KB The Efficacy, Safety, and Pharmacokinetics of ABI-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results From a Phase 1b Study 589.2 KB Presentations Assembly Biosciences Corporate Presentation
Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB
The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB
ABI-5366-101: A Phase 1b Study of a Novel, Oral, Long-Acting, Investigational HSV Helicase-Primase Inhibitor in Recurrent Genital Herpes 394.7 KB
The Efficacy, Safety, and Pharmacokinetics of ABI-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Interim Results From a Phase 1b Study 589.2 KB
